NOVAVAX, Inc. (NASDAQ:NVAX) is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, highly potent, recombinant vaccines utilizing a new, efficient manufacturing solution.
Recent Releases
- NOVAVAX Reports Additional Positive Data from its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy Adults
02/08/2010 - NOVAVAX Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration
02/08/2010 - NOVAVAX to Present at 12th Annual BIO CEO & Investor Conference
02/05/2010 - NOVAVAX to Present at Phacilitate Vaccine Forum Washington 2010
01/25/2010 - NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate
01/12/2010 - NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock
12/9/2009 - NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
12/02/2009 - NOVAVAX to Present at the Piper Jaffray 21st Annual Health Care Conference
11/30/2009 - NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults
11/30/2009 - NOVAVAX Prices Public Offering of Common Stock
11/20/2009 - NOVAVAX Announces Public Offering of Common Stock
11/20/2009 - NOVAVAX Completes First Stage of Enrollment in Pivotal H1N1 Influenza Vaccine Study in the Country of Mexico
11/16/2009 - NOVAVAX Begins Phase IIa Study of Seasonal Influenza Vaccine in Older Adults
11/10/2009 - NOVAVAVAX Reports Third Quarter 2009 Financial Results
11/05/2009 - NOVAVAX Announces Release Date of 2009 Third Quarter Financial Results and Investor Conference Call
10/30/2009 - NOVAVAX to Present at Oppenheimer 20th Annual Healthcare Conference
10/29/2009 - NOVAVAX Announces Poster Presentation at the 47th Annual Meeting of the IDSA
10/29/2009 - NOVAVAX and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India
10/28/2009 - NOVAVAX to Present at 8th Annual BIO Investor Forum 2009
10/23/2009 - NOVAVAX and Xcellerex Announce Collaboration to Develop Large-scale Manufacturing Process for 2009 H1N1 Influenza VLP Vaccine
10/22/2009 - NOVAVAX Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico
10/20/2009 - NOVAVAX Awarded NIH Grant for Respiratory Syncytial Virus (RSV) Vaccine Program
10/13/2009 - NOVAVAX CEO to Present at the World Vaccine Congress 2009, Lyon, France
10/6/2009 - NOVAVAX Announces Board of Director Changes
10/1/2009 - NOVAVAX Announces Positive Results for Second Phase II Clinical Trials of its Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine Candidate
9/1/2009 - NOVAVAX Reports Second Quarter 2009 Financial Results
8/7/2009 - NOVAVAX Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
8/6/2009 - NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone
8/5/2009 - NOVAVAX Announces Release Date of 209 Second Quarter Financial Results and Investor Conference Call
7/31/2009 - NOVAVAX Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advances Preclinical Studies
7/22/2009 - NOVAVAX Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
7/21/2009 - NOVAVAX Announces Repayment of $5 Million of Convertible Debt
7/15/09 - Cadila Pharmaceuticals Launches Joint Venture with Novavax in India
7/09/09 - Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain
6/30/09 - NOVAVAX Appoints Stanley Erck to Board of Directors
6/26/09 - Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particles
6/24/09 - NOVAVAX CEO to Present at Phacilitate Forum Barcelona 2009
6/18/00 - NOVAVAX and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate against the Novel Influenza A (H1N1) Virus
6/4/09 - NOVAVAX Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
5/5/09